Literature DB >> 20675668

Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community.

Ravi Dhingra1, Philimon Gona, Emelia J Benjamin, Thomas J Wang, Jayashri Aragam, Ralph B D'Agostino, William B Kannel, Ramachandran S Vasan.   

Abstract

AIMS: To evaluate the association of serum phosphorus with cardiac structure/function and incident heart failure. METHODS AND
RESULTS: We related serum phosphorus to echocardiographic left ventricular (LV) measurements cross-sectionally, and to incident heart failure prospectively in 3300 participants (mean age 44 years, 51% women) free of heart failure, myocardial infarction, and chronic kidney disease (estimated glomerular filtration rate [eGFR]<60 mL/min/1.73 m(2)). Cross-sectionally, serum phosphorus was related positively to LV mass, internal dimensions, and systolic dysfunction. On follow-up (mean 17.4 years), 157 individuals developed heart failure. In models adjusting for established risk factors as time-varying covariates, each mg/dL increment in serum phosphorus was associated with a 1.74-fold risk of heart failure [95% confidence intervals (CI) 1.17-2.59]. Individuals in the highest serum phosphorus quartile experienced a two-fold (95% CI 1.28-3.40) risk of heart failure compared with participants in the lowest quartile. These relations were maintained upon additional adjustment for LV mass/dimensions and systolic dysfunction. In analyses restricted to individuals with eGFR >90 mL/min/1.73 m(2), no proteinuria and serum phosphorus <4.5 mg/dL, the association of serum phosphorus with heart failure remained robust.
CONCLUSION: In our community-based sample, higher serum phosphorus was associated with greater LV mass cross-sectionally, and with an increased risk of heart failure prospectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675668      PMCID: PMC2913049          DOI: 10.1093/eurjhf/hfq106

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  33 in total

1.  The natural history of congestive heart failure: the Framingham study.

Authors:  P A McKee; W P Castelli; P M McNamara; W B Kannel
Journal:  N Engl J Med       Date:  1971-12-23       Impact factor: 91.245

2.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

3.  Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism.

Authors:  L M Resnick; F B Müller; J H Laragh
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

4.  Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?

Authors:  Armin Zittermann; Stefanie Schulze Schleithoff; Gero Tenderich; Heiner K Berthold; Reiner Körfer; Peter Stehle
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

5.  Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D.

Authors:  A A Portale; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

6.  Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.

Authors:  Emil Hagström; Per Hellman; Tobias E Larsson; Erik Ingelsson; Lars Berglund; Johan Sundström; Håkan Melhus; Claes Held; Lars Lind; Karl Michaëlsson; Johan Arnlöv
Journal:  Circulation       Date:  2009-05-18       Impact factor: 29.690

7.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

8.  Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia.

Authors:  Kerstin Amann; Johannes Törnig; Birgit Kugel; Marie-Luise Gross; Karin Tyralla; Abdussalam El-Shakmak; András Szabo; Eberhard Ritz
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

Authors:  Ramachandran S Vasan; Emelia J Benjamin; Martin G Larson; Eric P Leip; Thomas J Wang; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2002-09-11       Impact factor: 56.272

10.  Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans.

Authors:  A A Portale; B P Halloran; M M Murphy; R C Morris
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

View more
  37 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

2.  Serum Phosphate and Retinal Microvascular Changes: The Multi-Ethnic Study of Atherosclerosis and the Beaver Dam Eye Study.

Authors:  Rupal Mehta; Alexander Hodakowski; Xuan Cai; Kris E Lee; Bryan R Kestenbaum; Ian H de Boer; Amani Fawzi; Tien Yin Wong; Joachim Ix; Barbara Klein; Ronald Klein; Tamara Isakova
Journal:  Ophthalmic Epidemiol       Date:  2017-04-12       Impact factor: 1.648

3.  Effect of niacin on FGF23 concentration in chronic kidney disease.

Authors:  Madhumathi Rao; Michael Steffes; Andrew Bostom; Joachim H Ix
Journal:  Am J Nephrol       Date:  2014-05-20       Impact factor: 3.754

4.  Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study).

Authors:  Faye L Lopez; Sunil K Agarwal; Morgan E Grams; Laura R Loehr; Elsayed Z Soliman; Pamela L Lutsey; Lin Y Chen; Rachel R Huxley; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2012-12-28       Impact factor: 2.778

Review 5.  Phosphate is a vascular toxin.

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-11-17       Impact factor: 3.714

Review 6.  Coronary artery calcification in chronic kidney disease: An update.

Authors:  Tomasz Stompór
Journal:  World J Cardiol       Date:  2014-04-26

7.  Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Gui Shuang Ying; Samuel Houston; Tamara Isakova; Lisa Nessel; Akinlolu Ojo; Alan Go; Jim Lash; John Kusek; Juan Grunwald; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2015-04-24       Impact factor: 5.992

8.  Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease.

Authors:  Lac Tran; Michael Batech; Connie M Rhee; Elani Streja; Kamyar Kalantar-Zadeh; Steven J Jacobsen; John J Sim
Journal:  Nephrol Dial Transplant       Date:  2015-08-08       Impact factor: 5.992

9.  Cardiovascular effects of sevelamer in stage 3 CKD.

Authors:  Colin D Chue; Jonathan N Townend; William E Moody; Daniel Zehnder; Nadezhda A Wall; Lorraine Harper; Nicola C Edwards; Richard P Steeds; Charles J Ferro
Journal:  J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 10.121

10.  Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Pamela L Lutsey; Alvaro Alonso; Erin D Michos; Laura R Loehr; Brad C Astor; Josef Coresh; Aaron R Folsom
Journal:  Am J Clin Nutr       Date:  2014-07-16       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.